MAP Pharmaceuticals, Inc (MAPP)

[surf1944]

7:04AM MAP Pharma resubmits new drug application to FDA for LEVADEX orally inhaled migraine drug (MAPP) 16.00 : Co announced that it has resubmitted its New Drug Application to the United States Food and Drug Administration (FDA) for LEVADEX orally inhaled migraine drug for the potential acute treatment of migraine in adults. "We have worked diligently on our LEVADEX resubmission and, based on our dialogue with the FDA, we believe that we have addressed the issues outlined by the FDA in the Complete Response letter we received in March 2012," said Timothy S. Nelson, president and chief executive officer of MAP Pharmaceuticals